Compare FHTX & BRBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FHTX | BRBI |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United States | Brazil |
| Employees | N/A | 188 |
| Industry | Medicinal Chemicals and Botanical Products | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 323.4M | 293.2M |
| IPO Year | 2020 | N/A |
| Metric | FHTX | BRBI |
|---|---|---|
| Price | $5.57 | $11.43 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $11.50 | N/A |
| AVG Volume (30 Days) | ★ 242.3K | 234.0 |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 5.03% |
| EPS Growth | ★ 25.32 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,909,000.00 | N/A |
| Revenue This Year | $8.89 | N/A |
| Revenue Next Year | $20.13 | $17.24 |
| P/E Ratio | ★ N/A | $11.72 |
| Revenue Growth | ★ 36.75 | N/A |
| 52 Week Low | $3.27 | $10.90 |
| 52 Week High | $6.95 | $67.01 |
| Indicator | FHTX | BRBI |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
BRBI BR Partners SA, formerly BR Advisory Partners Participacoes SA, is engaged in investing in other companies, domestic or foreign, as a partner, quota holder, or shareholder, and management of its assets. It has a single reportable segment being investment banking services, which are administered and managed according to the products offered. However, the company divides it's operations into the following business lines: (1) investment banking and capital markets, (2) treasury sales & structuring, (3) investments and wealth management and (4) capital remuneration.